Bionano Genomics to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 1st, 2022
Bionano Genomics (BNGO) will host a conference call on March 1, 2022, at 4:30 p.m. ET to discuss its fourth quarter and year-end 2021 financial results and share recent corporate developments.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bionano Genomics (BNGO) will host a conference call on March 1, 2022, at 4:30 p.m. ET to discuss its fourth quarter and year-end 2021 financial results and share recent corporate developments. The call can be accessed via toll-free and international dial-ins, with a conference ID of 8795841. An archived version of the webcast will be available in the Investors section of the company's website. Bionano focuses on genome analysis, providing solutions and diagnostic services for biology and medicine.
Details
News Market Reaction – BNGO
The recorded move for BNGO in the trading session of this news was -6.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 1st, 2022 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2021 and to highlight recent corporate progress.
Conference Call & Webcast Details
| Date: | Tuesday, March 1st, 2022 |
| Time: | 4:30 p.m. Eastern Time |
| Toll Free: | 1-855-940-5312 |
| Toll/International: | 1-929-517-0416 |
| Conference ID: | 8795841 |
| Webcast: | https://edge.media-server.com/mmc/p/iy5k7mh6 |
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit bionanogenomics.com, lineagen.com or biodiscovery.com
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations and
Media Contact:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.